Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

r advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study by the end of 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-8040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of n
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014  Edison Nation Medical, ... partnership with the American Association for Respiratory Care ... respiratory care specialists. Edison Nation Medical, which brings ... business to commercialize their innovation ideas, will work ... of more than 50,000 respiratory therapists in bringing ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
(Date:9/2/2014)... (HealthDay News) -- A leading group of oncologists has ... form of advanced breast cancer. HER2-negative breast ... target the HER2 protein, the American Society of Clinical ... Almost 80 percent of women with advanced breast ... releasing this guideline, our aim is to improve both ...
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... 02, 2014 When weather conditions are right, ... night, leaving behind a path of destruction. In fact, the ... average of 1,253 tornadoes per year. Rainbow International offers the ... a tornado strikes., , Select a safe ... in your home with no windows to stay during the ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 Alliance ... targeting and multi-channel email marketing is pleased to announce ... market, Firearms & Freedom as well as ... properties represent more than one million concerned Americans who ... advertising. , “We are honored to continue providing ...
Breaking Medicine News(10 mins):Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3
... 2010 Onconova Therapeutics, Inc. is presenting new data ... summarizing several studies with the company,s radioprotectant Ex-RAD at ... (RRS), September 25-29 in Maui, Hawaii. In vivo ... significant increase in survival versus placebo-treated groups in mice ...
... place Jan. 13-16, 2011 at the Wynn Las Vegas. ... (each morning), observing differences in technique from a variety ... Lectures and plenary sessions will cover topics as bladder, ... to treat patients with benign prostate cancer. , Also ...
... CA September 27, 2010 Hoag Memorial ... for patient-specific vaccine therapy to treat metastatic melanoma. ... that patient-specific vaccines can sometimes induce durable complete ... in one particular patient who participated in the ...
... puts children with a chronic lung condition caused by ... to a study from Johns Hopkins Children,s Center published ... The researchers say their findings should prompt pediatricians ... for signs of lung disease and to discuss the ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, Sept. ... feared diseases on the planet, and the second leading cause ... is slowly conquering cancer, according to an assessment of cancer ... with the U.S. Centers for Disease Control and Prevention, the ...
... You,d think that people choosing to live near to outdoor ... BMI thanks to an increase in all that healthy outdoor ... Alberta study looking at the relationship between reasons for choosing ... that,s simply not the case. In fact researchers ...
Cached Medicine News:Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3Health News:Study shows patient-specific vaccines for metastatic melanoma may induce durable complete regression 2Health News:Daycare puts children with lung disease at risk for serious illness 2Health News:As Science Unlocks Secrets, Cancer Rates Fall 2Health News:As Science Unlocks Secrets, Cancer Rates Fall 3Health News:As Science Unlocks Secrets, Cancer Rates Fall 4Health News:Moving closer to outdoor recreation not a recipe for being more physically active 2
... Available in 6 popular colors ... Wide crescent shape to accommodate wheel ... exam. Strong, smooth and quiet elctro-mechanical ... top. 2 Position programmable memory Patient ...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
...
... construction for lifelong quality. Sealed hydraulic system ... movement. Soft, contoured cushions with heavy-duty upholstery ... slit lamp arm for easy, smooth, and ... lamp arm for easy access to children ...
Medicine Products: